CL2014002397A1 - Polipeptidos para usarse en el tratamiento y/o prevención de una infección fúngica ocasionada por malassezia spp. - Google Patents

Polipeptidos para usarse en el tratamiento y/o prevención de una infección fúngica ocasionada por malassezia spp.

Info

Publication number
CL2014002397A1
CL2014002397A1 CL2014002397A CL2014002397A CL2014002397A1 CL 2014002397 A1 CL2014002397 A1 CL 2014002397A1 CL 2014002397 A CL2014002397 A CL 2014002397A CL 2014002397 A CL2014002397 A CL 2014002397A CL 2014002397 A1 CL2014002397 A1 CL 2014002397A1
Authority
CL
Chile
Prior art keywords
polypeptides
prevention
treatment
fungal infection
infection caused
Prior art date
Application number
CL2014002397A
Other languages
English (en)
Inventor
Deborah O'niel
Derry Mercer
Colin Stewart
Original Assignee
Novabiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novabiotics Ltd filed Critical Novabiotics Ltd
Publication of CL2014002397A1 publication Critical patent/CL2014002397A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Polyamides (AREA)
CL2014002397A 2012-03-14 2014-09-10 Polipeptidos para usarse en el tratamiento y/o prevención de una infección fúngica ocasionada por malassezia spp. CL2014002397A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1204457.4A GB201204457D0 (en) 2012-03-14 2012-03-14 Polypeptides and their use
US201261620833P 2012-04-05 2012-04-05

Publications (1)

Publication Number Publication Date
CL2014002397A1 true CL2014002397A1 (es) 2015-02-27

Family

ID=46026493

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002397A CL2014002397A1 (es) 2012-03-14 2014-09-10 Polipeptidos para usarse en el tratamiento y/o prevención de una infección fúngica ocasionada por malassezia spp.

Country Status (17)

Country Link
US (1) US20140155321A1 (es)
EP (1) EP2825261A1 (es)
JP (1) JP2015516943A (es)
KR (1) KR20140138940A (es)
CN (1) CN104428036A (es)
AU (1) AU2013234122A1 (es)
CA (1) CA2866837A1 (es)
CL (1) CL2014002397A1 (es)
GB (1) GB201204457D0 (es)
HK (1) HK1201050A1 (es)
IL (1) IL234646A0 (es)
MX (1) MX2014010996A (es)
NZ (1) NZ700467A (es)
RU (1) RU2014139857A (es)
SG (1) SG11201405539QA (es)
WO (1) WO2013136040A1 (es)
ZA (1) ZA201407276B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6596098B2 (ja) * 2015-04-03 2019-10-23 イーエルシー マネージメント エルエルシー 毛髪処理組成物
JP6553961B2 (ja) * 2015-06-25 2019-07-31 花王株式会社 美白剤
JPWO2017047299A1 (ja) * 2015-09-15 2017-12-21 富士フイルム株式会社 注射用液剤組成物
CN109700834A (zh) * 2019-01-18 2019-05-03 上海市农业科学院 一种蛹虫草固体发酵物及其抗菌用途
CN115381928B (zh) * 2022-10-27 2022-12-27 山东中医药大学附属医院 一种真菌提取物在制备溃疡性结肠炎治疗药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606278UA (en) * 2004-08-18 2016-09-29 Novabiotics Ltd Peptide
GB0611115D0 (en) * 2006-06-06 2006-07-19 Novabiotics Ltd Compounds and their use
GB0702020D0 (en) * 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
GB0702022D0 (en) * 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
CA2708554C (en) * 2007-12-21 2014-04-22 Basf Se Anti-dandruff compositions containing peptides

Also Published As

Publication number Publication date
HK1201050A1 (en) 2015-08-21
AU2013234122A1 (en) 2014-10-16
US20140155321A1 (en) 2014-06-05
ZA201407276B (en) 2015-06-24
IL234646A0 (en) 2014-11-30
EP2825261A1 (en) 2015-01-21
WO2013136040A1 (en) 2013-09-19
MX2014010996A (es) 2014-10-13
KR20140138940A (ko) 2014-12-04
JP2015516943A (ja) 2015-06-18
RU2014139857A (ru) 2016-05-10
CN104428036A (zh) 2015-03-18
CA2866837A1 (en) 2013-09-19
SG11201405539QA (en) 2014-10-30
NZ700467A (en) 2016-08-26
GB201204457D0 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
HK1222766A1 (zh) 高效的抗贅生劑和抗增生劑
HK1223616A1 (zh) 多環氨基甲酰基吡啶酮化合物和其用於治療 感染的用途
HK1223615A1 (zh) 多環氨基甲酰基吡啶酮化合物和其用於治療 感染的用途
BR112016020199A2 (pt) Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
CL2015000450A1 (es) Métodos y composiciones para el tratamiento de una afección genética
BR112015001838A2 (pt) composições de inibidor de efluxo e métodos de tratamento utilizando o mesmo.
CL2014001858A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
BR112014032488A2 (pt) embalagem, e blanqueta
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
HK1208378A1 (en) Pharmaceutical composition for the treatment of fungal infections
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
CL2014002397A1 (es) Polipeptidos para usarse en el tratamiento y/o prevención de una infección fúngica ocasionada por malassezia spp.
EP2982680A4 (en) PROTAMINE PEPTIDOMIMETIC AND PHARMACEUTICAL ACCEPTABLE SALTS, AND USE THEREOF
BR112015005627A2 (pt) composto, composição farmacêutica, uso de composto, método de tratamento e invenção.
GB2556856B (en) Band-Fastened, Convenience-Packaging for storing absorbent personal care articles
BR112014032501A2 (pt) composto, e, composição farmacêutica.
CO6801770A2 (es) Uso de secnidazol en el tratamiento de infecciones dentales
LT3015109T (lt) Biologinis barjeras su simetikonu, skirtas panaudoti nosies-ryklės-vamzdelių infekcijų gydymui
AP2015008726A0 (en) Low-glycerin-formulations for hiv treatment and prevention
BR112016022438A2 (pt) composto, composição farmacêutica compreendendo o mesmo, e seu uso
TH1401003659A (th) ไนฟูราเทลซัลฟอกไซด์สำหรับการใช้ในการรักษาการติดเชื้อแบคทีเรีย
TH1301005823B (th) องค์ประกอบฆ่าวัชพืชที่ประกอบรวมด้วยฟลาซาซัลฟูรอน และเมทไตรบูซิน